<code id='158CB1806F'></code><style id='158CB1806F'></style>
    • <acronym id='158CB1806F'></acronym>
      <center id='158CB1806F'><center id='158CB1806F'><tfoot id='158CB1806F'></tfoot></center><abbr id='158CB1806F'><dir id='158CB1806F'><tfoot id='158CB1806F'></tfoot><noframes id='158CB1806F'>

    • <optgroup id='158CB1806F'><strike id='158CB1806F'><sup id='158CB1806F'></sup></strike><code id='158CB1806F'></code></optgroup>
        1. <b id='158CB1806F'><label id='158CB1806F'><select id='158CB1806F'><dt id='158CB1806F'><span id='158CB1806F'></span></dt></select></label></b><u id='158CB1806F'></u>
          <i id='158CB1806F'><strike id='158CB1806F'><tt id='158CB1806F'><pre id='158CB1806F'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:54
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Cassava Sciences’ Alzheimer’s clinical trials should be halted
          Cassava Sciences’ Alzheimer’s clinical trials should be halted

          MollyFerguson/STATTheFoodandDrugAdministrationshouldhaltCassavaSciences’ongoingclinicaltrialsinAlzhe

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          New England Journal of Medicine addresses racist history, slavery

          AdobeTheNewEnglandJournalofMedicine,theworld’soldestcontinuallypublishedmedicaljournal,publiclyrecko